NCT05038072View on ClinicalTrials.gov

The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

November 22, 2020

Study Completion Date

February 28, 2021

Conditions
Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

suprachoroidal injection of Triamcinolone Acetonide.

4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).

Trial Locations (1)

Unknown

Al Mouwasat University Hospital, Department of Ophthalmology, Damascus

All Listed Sponsors
lead

Damascus University

OTHER

NCT05038072 - The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter